FDx Advisors Inc. Buys 306 Shares of Becton, Dickinson and Company (BDX)
FDx Advisors Inc. grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 15,557 shares of the medical instruments supplier’s stock after acquiring an additional 306 shares during the period. FDx Advisors Inc.’s holdings in Becton, Dickinson and were worth $3,048,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the company. Alliancebernstein L.P. lifted its holdings in shares of Becton, Dickinson and by 0.8% in the first quarter. Alliancebernstein L.P. now owns 366,807 shares of the medical instruments supplier’s stock valued at $67,287,000 after purchasing an additional 2,817 shares in the last quarter. Spark Investment Management LLC purchased a new stake in shares of Becton, Dickinson and in the first quarter valued at $366,000. Montag & Caldwell LLC acquired a new position in shares of Becton, Dickinson and in the first quarter worth $34,713,000. AXA increased its stake in shares of Becton, Dickinson and by 7.1% in the first quarter. AXA now owns 420,553 shares of the medical instruments supplier’s stock worth $77,146,000 after acquiring an additional 27,846 shares during the last quarter. Finally, MAI Capital Management acquired a new position in shares of Becton, Dickinson and in the first quarter worth $218,000. Institutional investors own 86.01% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/fdx-advisors-inc-buys-306-shares-of-becton-dickinson-and-company-bdx/1702596.html.
Shares of Becton, Dickinson and Company (NYSE BDX) opened at $220.00 on Tuesday. The company has a quick ratio of 5.01, a current ratio of 5.56 and a debt-to-equity ratio of 1.48. The firm has a market cap of $49,889.07, a P/E ratio of 23.10, a P/E/G ratio of 1.72 and a beta of 1.04. Becton, Dickinson and Company has a fifty-two week low of $161.29 and a fifty-two week high of $225.23.
Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. During the same quarter in the previous year, the business earned $2.12 EPS. The business’s quarterly revenue was down 2.0% compared to the same quarter last year. research analysts expect that Becton, Dickinson and Company will post 10.63 EPS for the current year.
A number of equities analysts have recently weighed in on the stock. Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 price target on shares of Becton, Dickinson and in a research note on Friday, November 3rd. Morgan Stanley upped their price target on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Royal Bank Of Canada reissued a “sector perform” rating and set a $230.00 target price (up from $210.00) on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 target price on the stock in a research report on Tuesday, October 31st. Finally, Wells Fargo & Company reissued a “positive” rating and set a $235.00 target price (up from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $213.47.
In other Becton, Dickinson and news, EVP Linda M. Tharby sold 4,695 shares of Becton, Dickinson and stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total value of $941,253.60. Following the sale, the executive vice president now directly owns 18,670 shares in the company, valued at approximately $3,742,961.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction on Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the sale, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The disclosure for this sale can be found here. Insiders have sold a total of 47,038 shares of company stock valued at $9,480,225 in the last ninety days. Company insiders own 1.40% of the company’s stock.
About Becton, Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.